Pseudoephedrine
| Evidence Level: L4 | Predicted Indications: 3 |
Table of Contents
Pseudoephedrine: From Allergic Rhinitis to Nasal Cavity Disease
One-Sentence Summary
Pseudoephedrine is an oral nasal decongestant, originally used for allergic rhinitis, vasomotor rhinitis, the common cold and related upper airway conditions. The TxGNN model predicts it may be effective for Nasal Cavity Disease, but there are currently 0 registered clinical trials and only 7 publications (mostly preclinical models and a review) linked to this prediction. This is largely an extension of existing use rather than a true repurposing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, rhinitis, common cold, pharyngitis (the US license records contain no indication text; these come from the knowledge graph) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L4 |
| US Market Status | Cancelled only (all 3 listed licenses are cancelled) |
| Number of NDAs | 3 (ANDA/OTC monograph records, all cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, pseudoephedrine is an indirect sympathomimetic that releases norepinephrine and activates alpha-adrenergic receptors on nasal mucosal blood vessels. This causes vasoconstriction, reducing mucosal swelling and congestion.
“Nasal cavity disease” is a broad category that overlaps heavily with the drug’s existing indications (allergic rhinitis, vasomotor rhinitis, rhinitis, common cold). The decongestant mechanism applies to nasal congestion across allergic and non-allergic conditions, so the prediction is plausible. However, the benefit would be symptomatic relief of congestion, not treatment of the underlying disease.
Two other predictions were also generated: acute laryngopharyngitis (score 99.73%, no studies, Hold) and allergic urticaria (score 99.14%, no supporting evidence for pseudoephedrine, Hold). Neither has a convincing mechanistic link. Urticaria is histamine-driven, and pseudoephedrine has no antihistamine activity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22794679 | 2012 | Review | Allergy Asthma Proc | Overview of nonallergic rhinitis (inflammatory and noninflammatory causes) with nasal congestion as a shared symptom |
| 11345158 | 2001 | Clinical study (design not confirmed) | Am J Rhinol | Compared oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine on nasal cavity dimensions using acoustic rhinometry |
| 12962193 | 2003 | Preclinical (dog) | Am J Rhinol | Model of allergic nasal congestion in ragweed-sensitized dogs using acoustic rhinometry |
| 12387934 | 2002 | Preclinical (dog) | J Pharmacol Toxicol Methods | Pharmacological characterization of a chronic dog model of nasal congestion for studying decongestants |
| 11895194 | 2002 | Preclinical (dog) | Am J Rhinol | Dog model of compound 48/80-induced nasal congestion measured by acoustic rhinometry |
| 19769798 | 2009 | Preclinical (cat) | Am J Rhinol Allergy | Loratadine plus montelukast produced decongestion in a feline model; d-pseudoephedrine was also studied as a comparator |
| 24492651 | 2014 | Preclinical | J Pharmacol Exp Ther | Selective α2c-adrenergic agonists evaluated in animal models of nasal congestion (not pseudoephedrine) |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA075153 | Leader 12 Hour Sinus Nasal Decongestant (Cardinal Health) | Film-coated extended-release tablet | Not available (cancelled) |
| M012 | Nasal Decongestant (CVS Pharmacy) | Film-coated tablet | Not available (cancelled) |
| ANDA077442 | Pseudoephedrine Hydrochloride (Publix Super Markets) | Film-coated extended-release tablet | Not available (cancelled) |
All three authorizations are cancelled and none is currently valid. All listed forms are oral.
Safety Considerations
- Contraindications flagged in the knowledge graph (not taken from label text, so they need verification against the package insert): hypertension, coronary artery disease, congestive heart failure, stroke and cerebrovascular disorders, kidney disease, liver disease and liver failure, diabetes mellitus and diabetic ketoacidosis, hypothyroidism, epilepsy, COPD, peptic ulcer disease, benign prostatic hyperplasia, inflammatory bowel disease, pancreatitis, gallbladder disease, blood coagulation disease, rhabdomyolysis, and substance abuse/dependence. The cardiovascular and metabolic conditions are the most clinically relevant.
- Drug Interactions: 100 interactions were found; the 20 retrieved are mostly Moderate. They involve antidiabetic agents (acarbose, acetohexamide, alogliptin, canagliflozin, chlorpropamide, dapagliflozin, empagliflozin, glimepiride, glipizide, glyburide, insulins, exenatide, dulaglutide, albiglutide) and the anorectic diethylpropion. Ascorbic acid is a Minor interaction.
Please refer to the package insert for the official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction (nasal cavity disease) is biologically plausible but overlaps with existing indications, so it adds little new value. Evidence is limited to preclinical models, one review and one comparative clinical study, with no registered trials. All US licenses are cancelled, and label safety data are missing. The other two predictions (laryngopharyngitis, urticaria) lack supporting evidence.
To proceed, the following is needed:
- Package insert warnings and contraindications (safety screening cannot proceed without them)
- Mechanism of action data from DrugBank
- A defined, specific nasal condition beyond existing rhinitis and cold indications, with controlled clinical data
- Confirmation of current US regulatory and marketing status
- A review of cardiovascular and metabolic risk for the target population, given the knowledge-graph contraindications and antidiabetic interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.